News
ICCC
4.990
+2.05%
0.100
Weekly Report: what happened at ICCC last week (0303-0307)?
Weekly Report · 6d ago
Weekly Report: what happened at ICCC last week (0224-0228)?
Weekly Report · 03/03 11:21
ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
Barchart · 02/28 13:00
ImmuCell’s Earnings Call Highlights Robust Recovery
TipRanks · 02/28 00:57
ImmuCell Reports Strong Sales Growth and Recovery
TipRanks · 02/27 04:14
ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY
Benzinga · 02/25 21:10
IMMUCELL CORPORATION FY NET INCOME USD -2.157 MILLION
Reuters · 02/25 21:05
IMMUCELL CORP -QTRLY SHR LOSS $0.06
Reuters · 02/25 21:05
*Immucell 4Q Net $515,000 >ICCC
Dow Jones · 02/25 21:05
Press Release: ImmuCell Announces Unaudited -2-
Dow Jones · 02/25 21:05
Press Release: ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
Dow Jones · 02/25 21:05
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
Barchart · 02/25 15:05
Earnings Scheduled For February 25, 2025
Benzinga · 02/25 08:32
Weekly Report: what happened at ICCC last week (0217-0221)?
Weekly Report · 02/24 11:20
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
Barchart · 02/20 07:19
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell
NASDAQ · 02/18 14:48
Weekly Report: what happened at ICCC last week (0210-0214)?
Weekly Report · 02/17 11:18
Top Stock Reports for Apple, Eli Lilly & Shopify
NASDAQ · 02/14 22:54
Weekly Report: what happened at ICCC last week (0203-0207)?
Weekly Report · 02/10 11:12
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/04 12:05
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).